Clinical trials deliver medical breakthroughs – but how do they happen?
Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.
Search
New Platform: Unbridle Your Potential | Boehringer Ingelheim US
Read more on the Boehringer Ingelheim brand platform: Unbridle Your Potential, aimed at providing support and leadership for the equine industry.
Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
Growing with us
We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US
Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.
Innovation in Oncology and Cancer Immunology
Cancer research is one of the cornerstones of BI's research and has resulted in the launch of 2 products for the treatment of non-small cell lung cancer.
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim and Vanderbilt University join forces
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.
Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.
Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
Depression
Depression
Schizophrenia
Schizophrenia
Occupational Health and Safety
Occupational Health and Safety
Foot-and-Mouth-Disease Quick Response | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim's fight against foot-and-mouth disease (FMD), with our experts able to contain an outbreak in just six days.
Grass Roots Innovation Overview
Video providing an overview of the Grass Roots Innovation Program and how the activities support the next generation of life-science innovators and entrepreneurs
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Retinal Health
Retinal Health
Country Management Committee: A Message | Boehringer Ingelheim US
Click here to read a statement from Boehringer Ingelheim on the tragic events in Uvalde, TX and how BI Cares is supporting victims and families.
PetPro Connect: Veterinary Medicine in the Digital Age
Read more on PetPro Connect - the BI app & web portal, linking pet owners and veterinarians in a world transformed by digital health and new medicine.
Partnering Purpose: BI Gives Back | Boehringer Ingelheim US
Hear from Sheila Denton, Senior Vice President, General Counsel and Corporate Secretary, on the importance of giving back to our communities.
Age-Related Macular Degeneration | PDF
3FLEX® 250-Dose Option & Vaccine Mixing | Boehringer Ingelheim US
Click here to find out more about Boehringer Ingelheim's 3FLEX® 250-Dose option & new vaccine mixing procedures, preventing major swine respiratory disease.
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.